Legato Capital Management LLC Has $2.45 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Legato Capital Management LLC grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 48.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,364 shares of the biopharmaceutical company’s stock after purchasing an additional 9,541 shares during the quarter. Legato Capital Management LLC’s holdings in Intra-Cellular Therapies were worth $2,452,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. True Wealth Design LLC bought a new position in shares of Intra-Cellular Therapies in the third quarter valued at $32,000. GAMMA Investing LLC grew its position in shares of Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 240 shares during the period. Capital Performance Advisors LLP acquired a new position in shares of Intra-Cellular Therapies during the 3rd quarter worth about $74,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Intra-Cellular Therapies in the 3rd quarter valued at about $97,000. Finally, Quarry LP lifted its stake in Intra-Cellular Therapies by 260.0% in the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 1,300 shares during the last quarter. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ:ITCI opened at $127.56 on Wednesday. The business’s 50 day simple moving average is $102.37 and its 200 day simple moving average is $86.66. Intra-Cellular Therapies, Inc. has a 1 year low of $62.78 and a 1 year high of $128.00.

Insider Buying and Selling

In other news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at approximately $91,834,228.20. This represents a 4.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ITCI. StockNews.com initiated coverage on Intra-Cellular Therapies in a research note on Saturday. They set a “hold” rating for the company. Piper Sandler reaffirmed a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Baird R W downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. upped their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. Nine equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $103.62.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.